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TOXOPLASMOSIS AND THE LABORATORY: DIAGNOSIS AND A CONSTANT
STRIVING FOR IMPROVEMENT
Antonio Walter FERREIRA & Mário E. CAMARGO
Almost half a century has elapsed since the early studies of Sabin
and Feldman about the diagnosis of Toxoplasmosis. Traditional manual
laboratory methods adequate for small routines have been replaced with
automated or semi-automated procedures involving little manipulation
and risk of human error, which can be used for large routines at reasonable
prices.
Indeed, continuous scientific and technical evolution has led to a
decisive progress in diagnosis through the search of “gold standard”
tests that will provide safe information about the real health status of the
patient. However, in our opinion, faults are often observed in the training
of clinicians or laboratory technicians concerning the selection of tests
and mainly their use at an opportune time and the correct interpretation
of their results with respect to the clinical signs and symptoms presented
by the patients. Fortunately, great efforts are being made in this respect
both by Health Offices and by medical societies and entities in various
States in Brazil. The serological profiles observed during the course of
Toxoplasmosis are classical, respectively representing recent infection,
previous infection or a transition phase, and have been defined by
experienced investigators such as G. DESMONT in France, J.S.
REMINGTON in the United States, and others, including Brazilian
researchers, such as M.E. CAMARGO from this Tropical Medicine
Institute. Successively available immunological resources, such as the
Complement Fixation test, Indirect Hemagglutination and detection of
anti-Toxoplasma gondii IgG and IgM antibodies especially by ELISA
and Immunofluorescence, have been thoroughly investigated. For years
these serological profiles of toxoplasmosis have been exhaustively taught
at medical and paramedical schools and discussed at Congresses and
Scientific Meetings, being unanimously accepted in laboratory diagnostic
routine. However, technology has evolved, especially with the
development of more sensitive automated equipment. The Universities,
historical seats of research, have been rapidly superseded by large
industries which have heavily invested in the development of new
products and in equipment of high sensitivity. However, some errors
have started to arise especially in the search for IgM antibodies by
attributing excessive value to their residual levels, which are
nonsignificant and erroneously interpreted as positive results indicating
current infection, with serious consequences especially for women in
the early phase of pregnancy, who are submitted to unnecessary treatment
or even to interruption of pregnancy. Fortunately, research and
development have continued to advance and new parameters have been
developed for the diagnosis of toxoplasmosis in its different phases,
such as the avidity test of IgG antibodies and detection of the parasite by
a molecular method such as the polymerase chain reaction (PCR). IgG
antibodies of low avidity characterize the beginning of infection, being
present up to the third or fourth month, whereas the PCR method permits
to confirm fetal infection by detection of the parasite DNA in amniotic
fluid.
Thus, the following algorithm could be suggested for the diagnosis
of toxoplasmosis:
Search for IgG antibodies using a sensitive and specific automatic
method;
Search for IgM antibodies by immunocapture and, in the case of
their presence at levels exceeding those established by the manufacturer,
i.e., above the reactivity threshold of the test, use of the avidity test of
IgG antibodies.
When combined and properly interpreted, these tests help define the
disease, permitting the identification of important information that will
guide the conduct of the clinician in the “recent acute”, or “non-acute”
phase. Only the presence of IgG antibodies indicates immunity when
they are detected at satisfactory levels using highly specific reagents,
whereas IgM antibodies characterize current infection. The Indirect
Immunofluorescence test could be used in small routines, with care taken
to avoid false-positive IgM antibodies. All sera should be routinely
absorbed with RF absorbent before processing, a fact that makes the test
more onerous for the laboratories.
A serious mistake, unfortunately quite frequent and with often serious
consequences, is to consider pregnant women who are seronegative for
anti-toxoplasma antibodies to be at no risk to transmit toxoplasmosis to
the fetus. This is due to the fact that the professionals believe that this
serological negativity excludes maternal infection by toxoplasma, as
would be the case for negative tests for other conditions such as Chagas
disease, syphilis etc. In contrast, a negative serological test for
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toxoplasmosis requires frequent repetition in pregnant women throughout
gestation due to the risk of the mother to become infected since she has
no defense antibodies and therefore could transmit the parasite to the
fetus, who is highly vulnerable to severe mortal infection or serious
irreversible lesions, mainly of the brain. The tests should be repeated
monthly or at two month intervals while they remain negative, and if
positivity should occur it will be imperative to treat immediately both
the pregnant woman and the newborn.
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